Pharmaceutics_R&D
Follow
Find
3.8K views | +0 today
Pharmaceutics_R&D
Pharmaceutical companies R&D specifically in neuroscience, CNS disease, pain and electrophysiology
Your new post is loading...
Your new post is loading...
Scooped by Julien Hering, PhD
Scoop.it!

India Wants To Expand Price Controls On Drugs

India Wants To Expand Price Controls On Drugs | Pharmaceutics_R&D | Scoop.it

In another move that will worry multi-national drugmakers, India is looking to widen price controls to extend beyond generics to include branded drugs that are imported into the country, according to reports. The effort comes as the global pharmaceutical industry closely watches how the Indian government guards patent protection, an issue that is currently playing out in two controversial court cases. (...) - by Ed SilvermanPharmalot, September 6th, 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Elan faces uncertain future after Alzheimer's drug crash

Elan faces uncertain future after Alzheimer's drug crash | Pharmaceutics_R&D | Scoop.it

Irish drugmaker Elan ($ELN) fell hard on news that partners Johnson & Johnson ($JNJ) and Pfizer ($PFE) have iced a late-stage program to develop its experimental Alzheimer's drug bapineuzumab. And the key program's collapse revived speculation about the future of the pharma group with CEO Kelly Martin expected to leave and ongoing buzz about a potential sale of the company. - By Ryan McBrideFierceBiotech |August 7, 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Generic drugs have saved US $1 trillion in past 10 years

Generic drugs have saved US $1 trillion in past 10 years | Pharmaceutics_R&D | Scoop.it

This is a pharma news story about a new report by the Generic Pharmaceutical Association (GPhA) that shows US consumers and the healthcare system saved over $1 trillion by using generic prescription drugs in the past ten years. - by Hanna Blake on Pharmaphorum, 3rd August, 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

L'UE veut faciliter les essais pharmaceutiques

L'UE veut faciliter les essais pharmaceutiques | Pharmaceutics_R&D | Scoop.it

"L’UE veut contrôler les essais pharmaceutiques”, titre la Berliner Zeitung. Le projet de règlement, présenté le 17 juillet par le Commissaire à la Santé John Dalli, vise notamment à les faciliter.

Pour l’instant, l’industrie pharmaceutique, qui finance les essais cliniques internationaux, se heurte à de nombreuses différences juridiques au sein de l’UE, explique la Frankfürter Ründschau. Elle a donc déserté l’Europe pour procéder à ces essais de préférence dans les pays émergents. Le nombre des tests effectués en Europe est passé de 5 000 en 2007 à 2 800 en 2011. - Berliner Zeitung traduit dans presseurop.eu, 18 juillet 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

» Recherche clinique: EyeBrain intègre l’Institut du Cerveau et de la Moelle Epinière (ICM)

» Recherche clinique: EyeBrain intègre l’Institut du Cerveau et de la Moelle Epinière (ICM) | Pharmaceutics_R&D | Scoop.it

EyeBrain, société qui développe des dispositifs médicaux pour le diagnostic précoce de maladies neurologiques, a annoncé jeudi l’installation d’une de ses équipes scientifiques au sein de l’ICM (Institut du Cerveau et de la Moelle Epinière), situé à l’hôpital Pitié-Salpêtrière à Paris. Cette équipe sera pilotée par Magali Seassau, Directrice des études scientifiques chez EyeBrain, et aura pour objectif de nouer des échanges scientifiques avec les chercheurs de l’ICM et d’accélérer la mise au point d’outils de recherche clinique sur les maladies neurologiques. (...) - MyPharma Editions 13 juillet 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

AstraZeneca loses fight over antipsychotic drug generics

AstraZeneca loses fight over antipsychotic drug generics | Pharmaceutics_R&D | Scoop.it

AstraZeneca’s bid to block the US Food and Drug Administation’s (FDA) approval of generic versions of its antipsychotic drug, Seroquel, has been rejected by a Washington federal judge. AstraZeneca’s attempt to stop the approval, by suing the FDA on March 28, was on the grounds that generic versions would violate its exclusivity rights over certain safety information. - by Hannah Blake on pharmaphorum.com 12th July 2012

more...
No comment yet.
Rescooped by Julien Hering, PhD from L'industrie pharmaceutique
Scoop.it!

Boehringer Ingelheim lance « BioXcellence » : sa marque pour ses activités de fabrication sous contrat

Boehringer Ingelheim lance « BioXcellence » : sa marque pour ses activités de fabrication sous contrat | Pharmaceutics_R&D | Scoop.it

Avec « Boehringer Ingelheim BioXcellence », le laboratoire pharmaceutique allemand a mis en place sa propre marque pour son activité de fabrication sous contrat de produits biopharmaceutiques. Cette dernière a été lancée officiellement lors du BIO US qui s’est déroulée à Boston du 18 au 21 juin 2012.


« Notre nouvelle marque Boehringer Ingelheim BioXcellence aidera nos clients et le marché à identifier la qualité et la fiabilité qui ont fait de l’activité de fabrication sous contrat de produits biopharmaceutiques de Boehringer Ingelheim l’une des plus importantes au monde », a souligné Simon Sturge, vice-président senior pour les produits biopharmaceutiques chez Boehringer Ingelheim.

 

Boehringer Ingelheim BioXcellence propose à l’industrie biopharmaceutique des services personnalisés de développement et de fabrication sous contrat, sur toute la chaîne de production technologique depuis l’ADN jusqu’aux activités de remplissage et de finition, sous un même toit, dans ses installations de Biberach (Allemagne), Vienne (Autriche) et Fremont (Etats-Unis


Parallèlement à la nouvelle marque, la société lance également son nouveau site internet, www.bioxcellence.com, qui est consacré à ses services de développement et de fabrication sous contrat.


Via Thibaud Guymard
more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Computer Model Successfully Predicts Drug Side Effects

Computer Model Successfully Predicts Drug Side Effects | Pharmaceutics_R&D | Scoop.it

UCSF Approach Could Improve Safety, Decrease Costs Of Drug Development. 

A new set of computer models has successfully predicted negative side effects in hundreds of current drugs, based on the similarity between their chemical structures and those molecules known to cause side effects, according to a paper appearing online this week in the journal Nature. - www.ucsf.edu

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

NIH, Companies Team Up to Give Researchers Access to Abandoned Drugs

NIH, Companies Team Up to Give Researchers Access to Abandoned Drugs | Pharmaceutics_R&D | Scoop.it

The National Institutes of Health (NIH) today announced a new plan for boosting drug development: It has reached a deal with three major pharmaceutical companies to share abandoned experimental drugs with academic researchers so they can look for new uses. NIH is putting up $20 million for grants to study the drugs. - ScienceInsider

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Maladies rares: Rhenovia lance des programmes de recherche de nouveaux médicaments

Maladies rares: Rhenovia lance des programmes de recherche de nouveaux médicaments | Pharmaceutics_R&D | Scoop.it

Rhenovia Pharma, société biotechnologique basée à Mulhouse et spécialisée dans la biosimulation appliquée à la recherche de nouveaux médicaments pour le traitement de maladies neurodégénératives, neurologiques, et psychiatriques, a annoncé hier le lancement de programmes de recherche de nouveaux médicaments ciblant les maladies rares, orphelines et négligées. - MyPharma Editions

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

CNS drugs take 35% longer to develop than others: study

CNS drugs take 35% longer to develop than others: study | Pharmaceutics_R&D | Scoop.it

Drugs being developed for the treatment of diseases of the central nervous system (CNS) take 35% longer to complete clinical trials and receive regulatory approval than other new prescription medicines, according to a new analysis. (PharmaGossip) 

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Sanofi CEO: Who Needs Big Pharma Scientists?

Sanofi CEO: Who Needs Big Pharma Scientists? | Pharmaceutics_R&D | Scoop.it

Who needs those pesky scientists? At least those who work at big pharma? After all, the best ones want to work at smaller biotechs, right? And those left behind have no idea how to innovate. Says who? Chris Viehbacher, that’s who. The Sanofi ceo let loose at the CED Life Sciences Conference this week, MedCity News reports, and was not shy about saying what he thinks. - Pharmalot

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Neurosciences : collaboration entre l’indien Jubilant et l’américain Mnemosyne

Neurosciences : collaboration entre l’indien Jubilant et l’américain Mnemosyne | Pharmaceutics_R&D | Scoop.it

Jubilant Biosys, la société pharmaceutique basée à Bangalore en Inde et la société américaine de biotechnologie Mnemosyne Pharmaceutical ont annoncé aujourd’hui la signature d’un accord de collaboration en termes de découverte de médicaments avec qui aura pour objectif d’identifier des produits en phase préclinique dans le domaine des pathologies neuropsychiatriques. - MyPharma Editions

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Genentech's Alzheimer's antibody trial to study disease prevention

Genentech's Alzheimer's antibody trial to study disease prevention | Pharmaceutics_R&D | Scoop.it

The first clinical trial of a drug's ability to forestall Alzheimer's disease in cognitively healthy individuals is preparing to launch. Genentech of S. San Francisco, California, the Banner Alzheimer's Institute in Phoenix,…- by Ken GarberNature Biotechnology 30, 731–732, 7 August 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Was MedImmune worth $15.6 billion?

Was MedImmune worth $15.6 billion? | Pharmaceutics_R&D | Scoop.it

While AstraZeneca has made MedImmune the hub of its biologics division, a blockbuster drug has yet to come to market.
The region’s biotechnology industry hit a fever pitch five years ago this summer after a series of acquisitions, none of them more staggering than when British drugmaker AstraZeneca shelled out $15.6 billion for Gaithersburg-based MedImmune.
The deal at the time left some in the industry, especially locals, celebrating the hefty sticker price and others scratching their head — was MedImmune really worth more than the gross domestic product of many developing countries? (...) - by Steven Overly, The Washington Post, August 5, 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Alzheimer’s drug fails to show effectiveness in late-stage trial

Alzheimer’s drug fails to show effectiveness in late-stage trial | Pharmaceutics_R&D | Scoop.it

A drug developed by Pfizer, Johnson & Johnson and Elan Corp. to treat Alzheimer’s failed to slow the disease in a late-stage trial, Pfizer announced late yesterday. Following the release of the news, shares for the three companies dropped. Interestingly, a slight drop in shares was seen for Pfizer and J&J, down less than 1%, but Elan plunged 14%.

The Alzheimer’s treatment (bapineuzumab) is one of three experimental Alzheimer’s drugs undergoing late-stage patient tests. Approximately 35 million people worldwide have dementia, with Alzheimer’s being the most common type. Given its prevalence, the three potential treatments are being closely watched by doctors, patients, investors and analysts. (...) - by Rebecca Aris in Pharmaphorum, 24th July, 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

SLA: Biogen Idec va collaborer avec des instituts de recherche en vue de séquencer le génome de patients atteints

La société Biogen Idec a annoncé aujourd’hui qu’elle avait conclu une collaboration de recherche avec des instituts universitaires et de recherche majeurs pour séquencer le génome de jusqu’à 1 000 patients atteints de sclérose latérale amyotrophique (SLA) en vue de mieux comprendre les causes génétiques profondes de cette maladie. (...) - MyPharma Editions, 17 juillet 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

First therapy targeting Parkinson's proteins enters clinical trials

First therapy targeting Parkinson's proteins enters clinical trials | Pharmaceutics_R&D | Scoop.it

Parkinson's disease is driven by the slow and steady death of dopamine-producing neurons—and there's currently little modern medicine can do to stop the process. Dopamine replacement therapies such as levodopa help alleviate some of the more debilitating movement problems, but all the while brain cells continue to die and the neurodegenerative disorder gets worse. That's why the research community was buoyed last month by the announcement that an Austrian company had launched the world's first clinical trail involving a therapy directed against alpha-synuclein, a protein found to be a pathologic hallmark of Parkinson's disease. (...) - by Elie Dolgin in Nature Medicine 18, 992–993 (2012)

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

La Pharma française sur les réseaux sociaux (BioFutur)

La Pharma française sur les réseaux sociaux (BioFutur) | Pharmaceutics_R&D | Scoop.it

Biofutur publie une intéressante étude par 2 enseignantes de Grenoble au sujet de la présence de la Pharma française (ou filiales françaises des grands groupes) sur les réseaux sociaux. (...) 

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Medical Innovation Needs Silicon Valley Speed, Stat

Medical Innovation Needs Silicon Valley Speed, Stat | Pharmaceutics_R&D | Scoop.it

The U.S. medical discovery-to-patient process moves at a glacial pace and is in desperate need of an overhaul; lessons learned in Silicon Valley can be applied to eliminate bottlenecks. - fastcompany.com

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Merck Serono annonce la fermeture de son siège à Genève

Merck Serono annonce la fermeture de son siège à Genève | Pharmaceutics_R&D | Scoop.it

Le groupe pharmaceutique Merck a annoncé mardi ses plans pour la réorganisation de Merck Serono en Suisse, dans le cadre du programme global de transformation annoncé en février. Merck projette des réductions d’effectifs sur plusieurs de ses sites basés en Suisse et a l’intention de transférer certaines des fonctions basées à Genève vers l’Allemagne, les Etats-Unis et la Chine. Les sites de production biotechnologique d’Aubonne (Vaud) et de Corsier-sur-Vevey (Vaud) seront maintenus. - MyPharma

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Genzyme servira de modèle à la recherche du groupe

La richesse de la filiale américaine réside aussi dans une approche plus efficace de la recherche scientifique.

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Diagnosing the decline in pharmaceutical R&D efficiency

Diagnosing the decline in pharmaceutical R&D efficiency | Pharmaceutics_R&D | Scoop.it

The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (R&D). Yet the number of new drugs approved per billion US dollars spent on R&D has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining R&D efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research–brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in R&D efficiency. (Nature Rev. Drug discovery 11, 2012)

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

» Alzheimer’s Drugs May Carry Negative Side Effects - Psych Central News

» Alzheimer’s Drugs May Carry Negative Side Effects - Psych Central News | Pharmaceutics_R&D | Scoop.it

Alzheimer’s medications currently in trial may actually act like a bad electrician, miswiring neurons and interfering with their ability to communicate with the brain, according to new Northwestern Medicine research.

more...
No comment yet.